This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Single Ascending Dose Study (SAD) iv Formulation (2006-006253-27)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: May 30, 2008
Last updated: December 1, 2010
Last verified: December 2010
The purpose is to study the safety of AZD1305, how AZD1305 is tolerated and how the medication is metabolised by the body (how it is taken up into the body, distributed around the body and disappears from the body

Condition Intervention Phase
Healthy Drug: AZD1305 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: A Single-centre, Single-blind, Randomised, Placebo-controlled, Single-dose Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Ascending Intravenous Doses of AZD1305 in Helahty Male Volunteers

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Adverse events, ECG variables, vital signs, physical examination, laboratory variables, body temperature and weight [ Time Frame: During the study ]

Secondary Outcome Measures:
  • Pharmacokinetic variables [ Time Frame: During all dosing visits ]

Enrollment: 36
Study Start Date: January 2008
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
AZD1305 solution for iv infusion
Drug: AZD1305
Solution for iv infusion , single dose
Placebo Comparator: B
NaCl solution for iv infusion
Drug: Placebo
NaCl solution for iv infusion, single dose


Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers
  • BIM 19-30 kg/m2

Exclusion Criteria:

  • Potassium outside normal reference values
  • ECG findings outside normal range
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00688831

Research Site
Uppsala, Sweden
Sponsors and Collaborators
Study Director: Helen Lunde, MD AstraZeneca R&D Mölndal, Sweden
Principal Investigator: Marianne Hartford, MD, PhD AstraZeneca, Clinical Pharmacology Unit, Sahlgrenska University Hospital, Göeborg, Sweden
  More Information

Responsible Party: Helen Lunde, MD, Medical Science Director, Emerging Arrythmias & Lipids, AstraZeneca Identifier: NCT00688831     History of Changes
Other Study ID Numbers: D3190C00002
Study First Received: May 30, 2008
Last Updated: December 1, 2010

Keywords provided by AstraZeneca:
Safety and tolerability

Additional relevant MeSH terms:
Pharmaceutical Solutions processed this record on August 16, 2017